Uk Startup 1nhaler Secures £1.5M Funding

The funding round was led by Archangels, with participation from Scottish Enterprise and BBB Investments.

The company plans to use the funds to advance its platform technology toward its first Marketing Authorisation Application (MAA) expected in late 2027. This includes producing clinical materials for regulatory studies and developing large-scale commercial manufacturing processes.

Read Also - European life Sciences VC Firm Medicxi Closes €500M Fund V

Founded by Don Smith and Lisa McMyn, 1nhaler develops inhalable drug delivery devices. Its single-dose DPI platform aims to overcome key challenges in current delivery options, improving user accessibility, reducing cost, enhancing performance, and minimizing environmental impact.

Its DPI is primarily made from eco-friendly cardboard and is the size and shape of a credit card for easy portability. The technology features a patent-protected membrane-based system that unfolds into a three-dimensional inhaler for patient use and can effectively deliver various dry powder drugs.

This follows an initial £2 million funding round in 2023, which was also led by Archangels.

About 1nhaler

Founded in 2017 1nhaler develops a compact, single-dose dry-powder inhaler that is easy to use, low-cost, and wallet-sized. Made mostly from cardboard and propellant-free, it unfolds into a 3D inhaler. Its patented membrane technology supports various medicines, aiming to expand access to life-saving inhalable treatments worldwide.